challeng downgrad
commerci momentum incumb
pressur share assumpt delay clinic
timelin creat catalyst void next month
see risk clinic differenti downgrad
equal-weight pt
path toward share gain look labor prior overweight
thesi predic materi market share gain tam
expans initi senza clinic superior market
see risk element
share gain like limit given stronger incumb
respons lead us lower estim consensu
major clinic data catalyst event earliest
creat near-term catalyst void
saluda privat cover evok studi like januari
lesser extent litig novemb risk senza
clinic messag reson expect lead us reduc
estim consensu previous discuss competit
risk ail senza year ago commerci messag around clinic
superior reson well sinc initi concern competitor
gain traction blunt share gain sinc nan
channel dilig shift recent month doctor highlight lower
real-world efficaci vs senza-rct subject pain score reduct
durabl relief altern therapi particularli intellis/evolv
workflow suggest commerci path like get harder
addit season recoveri like look beyond
consensu estim impli similar y/i us share gain pt
mse view unlik given aforement dynam
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
lower revenu estim consensu
reflect bp y/i us share gain
sit clinic catalyst void disrupt competit data could come
nan could disrupt share sit clinic
catalyst void senza-pdn/senza-nsrbp earlier avalon
studi saluda technolog achiev month respond rate
back leg pain versu senza senza-rct see
risk evok studi could show similar better efficaci senza
passiv stake saluda posit data like
bring anoth legitim player market stronger incumb push
potenti acquisition/partnership model market
model current account saluda risk litig
novemb less concern tail risk risk/reward trial
downgrad equal-weight price target may still
outgrow market see slower growth like lower share
gain margin assumpt reflect increas competit spend
move price target base busi tam
expans reflect sale similar multipl prior
price target lower revenu select high-growth smid
peer think inconsist execut slow growth potenti
risk hf therapi differenti later year warrant discount
could wrong share less expens select smid cap
peer implant includ could see season recoveri
segment could ripe consolid could
catalyst risk
pleas see insid detail chang financi assumpt market
price target deriv discount cash flow
valuat assum ww termin share margin
wacc yield today one year
ad valu expans place price target
painlessli disrupt gain materi share face increas
competit captur market share time margin reach
addit make substanti progress expans opportun
arriv earlier expect
painlessli disrupt captur us market
share gain labor given competit market
track gain us share time clinic catalyst around
expans like materi leav catalyst void
competit respons creat headwind progress date low-hang
fruit share gain stagnat increas spend push back profit
timelin us market share top high teen valuat contract
guidanc look achiev us
still see outgrow
market howev path addit share
gain harder given increas
competit competitor traction
clinic data expand
key data pain diabet neuropathi
non-surg back come
suggest clinic catalyst void
interim
senza superior could risk later
year competitor data less
concern tail risk exist litig
pt ww share increas
revenu
pt us share increas
revenu
pt us market growth assum
pro rata share increas revenu
bp
competit launch data on-going
risk achiev price
acceler competitor product
develop product uptak
current rep/physician relationship
stronger anticip
confid ip posit
patent litig may key risk time
path toward share expans look labor downgrad equal-weight
prior overweight thesi base three compon could gain
materi share fast-grow spinal cord stimul market compani
would materi expand total address market new dataset
indic high-frequ hf therapi differenti superior
current treatment option howev see risk element
downgrad share equal-weight
share gain like limit given faster market growth stronger
incumb respons compani spread commerci share gain erod
lead us lower estim consensu channel
dilig shift recent month
clinic timelin delay place us catalyst void enrol clinic timelin
delay diabet neuropathi pdn non surgic back nsrbp
earliest creat near-term catalyst void drive expans estim
time see risk hf clinic differenti prior
catalyst saluda privat cover evok studi like januari
lesser extent litig novemb risk senza
price target move lower ww us share
assumpt pt respect lower margin
assumpt reflect increas spend competit price target move
base busi expans reflect
sale similar multipl prior price target lower
revenu risk downgrad price target includ share less expens
select smid cap peer implant includ could see season
recoveri segment could ripe consolid
could catalyst risk
commerci messag reson well expect catalyz
us market growth mid-teen versu mid-singl digit prior follow
competit respons risk highlight ail senza
note year ago past januari nan commerci messag
clinic superior therapi reson broadli hope like
continu stick messag go forward meanwhil competitor messag
shift substanti focu novel waveform algorithm
despit less efficaci data date competitor gain materi traction
market abbott burst intelli evolv workflow
channel dilig shift ail senza also discuss senza real-world
result potenti headwind time dilig indic senza still
deliv superior result practic howev channel dilig shift
recent month doctor highlight lower real-word efficaci senza seen
senza-rct subject pain score reduct across differ compani
durabl relief altern therapi suggest commerci path
like get harder easier posit feedback evolv
workflow particular notabl
continu expect market grow teen commentari major
player indic expect low mid-teen growth estim us
market grew model us market grow year
next year continu driver market growth includ better efficaci newer
product primarili intelli boston wavewrit increas
incumb market push opioid crisi expect major player grow
least doubl digit year pleas see exhibit copi market model
pace share gain slow guidanc look achiev
beatabl path gain increment share harder result increas
incumb competit acceler market growth particular medtron
repres us market declin mid-singl
digit grown last two quarter last year follow
season weak revenu ultim exceed top end
guidanc rang continu expect season stronger
see lower likelihood similar upsid annual guidanc
given implic share gain beat top end guidanc
upsid come us would impli pt share gain
year look aggress us
revenu estim come consensu
lower top-line estim reduct
consensu estim estim reflect us revenu
bp y/i share gain ou estim cc
growth remain unchang model us market grow next year
note everi bp us share equat increas revenu
think consensu estim current impli similar us share gain
pt think unlik share gain becom
harder previous expect profit see
compani becom profit result increas spend degre
see signific upsid result estim could prove
expans initi push back month versu initi
expect discuss total address market initi
length recent recent pdn deep dive key data catalyst
senza-pdn senza-nsrbp given size market
see upper limb neck uln label may file later year
market abdomin pain still earli compani expect give
addit updat recent commentari push timelin back month
versu initi expect
senza-pdn senza-pdn larg scale random clinic trial rct
pain diabet neuropathi expect read versu initi
expect nan januari like slower enrol
senza-nsrbp senza-nsrbp rct non-surg refractori back pain
recent split two separ european us studi european studi
start enrol farther along us studi still earli
stage recent commentari indic like event
like catalyst void interim continu see
fulli price share current level howev practic key clinic
catalyst like least year away suggest middl catalyst
pushback clinic timelin particularli pdn led us lower tam
expans estim also taken conserv approach
term market penetr margin ramp assign tam
expans initi price target valuat methodolog vs prior
separ earlier analysi suggest pdn alon could worth valu
slower enrol senza-pdn suggest could difficult build
commerci channel previous anticip incorpor pdn
non-surg back expans dcf price target exhibit
expans dcf use wacc termin growth rate
present valu
pv
pv termin valu
one year valu
risk high frequenc therapi differenti
see risk hf differenti await key data catalyst high-frequ
hf therapi differenti therapi
superior label versu tradit treatment see potenti risk saluda
evok studi asra nan secondli hf ip
lawsuit goe trial novemb odd seem strongli favor
saluda evok system could statist superior tradit without use
hf therapi saluda privat cover evok system record respons
neuron stimul electr evok compound action potenti ecap
program automat adjust stimul level patient prefer
level compani call close loop system result avalon studi
show back leg pain respond rate respect month
compar favor pivot senza-rct shown follow exhibit
though avalon studi size smaller patient month versu senza-
rct senza control group month
evok studi double-blind random studi like read asra
nan evok studi double-blind random studi
one arm use evok system tradit arm
use evok closed-loop automat stimul therapi primari endpoint
composit endpoint wherebi success defin reduct va pain score
greater equal equival respond rate senza-rct
increas baselin pain medic studi double-blind remind
senza-rct blind discuss initi
unavoid given control group paresthesia experiment arm
senza estim primari complet date evok studi current
list may think data could come later year asra
statist signific result evok studi would neg affect
commerci messag view current hf therapi therapi
superior label tradit key market messag
behind senza burst abbott show superior tradit
sunburst trial magnitud smaller therapi
superior label evok show superior tradit possibl without hf
therapi magnitud senza would affect messag would erod
hf differenti think respons would focu lack
paresthesia senza evok still paresthesia convinc
enough off-set
model account saluda could creat fifth player stronger
incumb posit data evok bring legitim fifth
player market stronger incumb push
acquisit partnership given current passiv stake
saluda model market model current account saluda
boston engag litig surround hf intellectu
properti ip trial come novemb novemb file lawsuit
patent infring boston scientif relat therapi given boston
use hf therapi clinic trial acceler trial veloc trial
europ potenti hf launch follow data manufactur hf capabl
product us litig set go trial novemb year
odd seem strongli favor risk/reward look unfavor given signific
downsid could occur neg scenario remov hf ip
author materi act capac attorney hold
materi intend either legal opinion legal
advic inform provid herein provid possibl outcom
probabl outcom result legal disput controversi depend
varieti factor includ limit parti histor relationship law
pertain case rel litig talent trial locat juri composit judg
composit investor contact legal advisor issu law relat
subject matter materi
chang model
reduc estim share assumpt model discuss
top-line estim come consensu result
slower share gain us market model ww us
share pt lower prior forecast forecast
compound-annual-growth-rate ww us market bp higher
prior also lower margin assumpt take account higher
spend light increas competit
price target price target move base busi
expans base busi dcf use wacc termin growth rate
peak margin expans dcf use wacc termin
growth rate peak margin price target reflect
sale similar multipl prior price target lower revenu
select high-growth smid peer think inconsist
execut slow growth potenti risk hf therapi differenti later
year warrant discount
could wrong share less expens select smid cap peer
implant includ could see season recoveri
segment could ripe consolid
accret redeem convert prefer stock redempt valu
dollar million except per share data
good sold
dollar million except per share data
dollar million except per share data
accumul comprehens loss
dollar million except per share data
non-cash loss extinguish debt
payment origin issu discount
provis doubt account
write-down inventori
unreal loss foreign currenc transact
purchas short-term invest
proce matur short-term invest
chang restrict cash
proce issuanc common stock underwritten public offer
proce issuanc convert note
convert note initi issuanc discount debt issuanc costs-
proce issuanc warrant
purchas convert note hedg
repay debt
purchas common stock proce issuanc common stock stock option exercis
begin period
end period
sale
sale
chang work capit
sale
pv
weight averag capit wacc
equiti
margin debt
after-tax debt
pv free flow
pv termin valu
pv tax benefit
mv equiti invest
one year valu
total
present valu
pv
pv termin valu
one year valu
million
